TGF-β antibody uptake in recurrent high-grade glioma imaged with 89Zr-fresolimumab PET

Journal of Nuclear Medicine

Volumn 56, Issue 9, 2015, Pages 1310-1314

  Den Hollander, Martha W ^a   Bensch, Frederike ^a   Glaudemans, Andor W J M ^b   Oude Munnink, Thijs H ^a   Enting, Roelien H ^a   Den Dunnen, Wilfred F A ^a   Heesters, Mart A A M ^a   Kruyt, Frank A E ^a   Lub De Hooge, Marjolijn N ^a,b   De Groot, Jan Cees ^a   Pearlberg, Joseph ^c   Gietema, Jourik A ^a   De Vries, Elisabeth G E ^a   Walenkamp, Annemiek M E ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

^c Sanofi US   (United States)

Author keywords

89Zr fresolimumab; PET imaging; Recurrent high grade glioma; TGF

Indexed keywords

FRESOLIMUMAB; FRESOLIMUMAB ZR 89; RADIOPHARMACEUTICAL AGENT; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; RADIOISOTOPE; ZIRCONIUM;

ACNE; ADULT; AGED; ANEMIA; ANTIBODY TITER; BLOOD TOXICITY; BRAIN TISSUE; CANCER GRADING; CANCER RECURRENCE; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG PENETRATION; DRY SKIN; EPISTAXIS; FATIGUE; FEMALE; GLIOBLASTOMA; GLIOMA; HEADACHE; HUMAN; IMAGE ANALYSIS; LEUKOPENIA; MALE; NAUSEA; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BLOOD LEVEL; SKIN DISEASE; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY PET; ANIMAL; BRAIN NEOPLASMS; IMMUNOLOGY; METABOLIC CLEARANCE RATE; METABOLISM; MIDDLE AGED; PROCEDURES; SCINTISCANNING; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; AGED; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; CELL LINE, TUMOR; FEMALE; GLIOMA; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; RADIOISOTOPES; RADIOPHARMACEUTICALS; TISSUE DISTRIBUTION; TRANSFORMING GROWTH FACTOR BETA; ZIRCONIUM;

EID: 84940971189     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.154401     Document Type: Conference Paper

References (24)

1. Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14(suppl 5):v1-v49.
2. Massagué J. TGFβ in cancer. Cell. 2008;134:215-230.
3. Wesolowska A, Kwiatkowska A, Slomnicki L, et al. Microglia-derived TGF-β as an important regulator of glioblastoma invasion: an inhibition of TGF-β-dependent effects by shRNA against human TGF-β type II receptor. Oncogene. 2008;27:918-930.
4. Eichhorn PJ, Rodon L, Gonzalez-Junca A, et al. USP15 stabilizes TGF-β receptor I and promotes oncogenesis through the activation of TGF-β signaling in glioblastoma. Nat Med. 2012;18:429-435.
5. Kjellman C, Olofsson SP, Hansson O, et al. Expression of TGF-β isoforms, TGF-β receptors, and SMAD molecules at different stages of human glioma. Int J Cancer. 2000;89:251-258.
6. Schneider T, Sailer M, Ansorge S, Firsching R, Reinhold D. Increased concentrations of transforming growth factor β1 and β2 in the plasma of patients with glioblastoma. J Neurooncol. 2006;79:61-65.
7. Bruna A, Darken RS, Rojo F, et al. High TGFβ-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007;11:147-160.
8. Arjaans M, Oude Munnink TH, Timmer-Bosscha H, et al. Transforming growth factor (TGF)- β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. Pharmacol Ther. 2012;135:123-132.
9. Lonning S, Mannick J, McPherson JM. Antibody targeting of TGF-β in cancer patients. Curr Pharm Biotechnol. 2011;12:2176-2189.
10. Morris JC, Tan AR, Olencki TE, et al. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma [abstract]. PLoS One. 2014;9:e90353.
11. Stevenson JP, Kindler HL, Papasavvas E, et al. Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients [abstract]. Oncoimmunology. 2013;2:e26218.
12. Lampson LA. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs. 2011;3:153-160.
13. Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, et al. PET with the 89Zrlabeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med. 2011;52:2001-2008.
14. Loening AM, Gambhir SS. AMIDE: a free software tool for multimodality medical image analysis. Mol Imaging. 2003;2:131-137.
15. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990;8:1277-1280.
16. Van Asselt SJ, Oosting SF, Brouwers AH, et al. Everolimus reduces 89Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors. J Nucl Med. 2014;55:1087-1092.
17. Trachtman H, Fervenza FC, Gipson DS, et al. A phase 1, single-dose study of fresolimumab, an anti-TGF-β antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney Int. 2011;79:1236-1243.
18. Dijkers EC, Oude Munnink TH, Kosterink JG, et al. Biodistribution of 89Zrtrastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87:586-592.
19. Sigmond J, Honeywell RJ, Postma TJ, et al. Gemcitabine uptake in glioblastoma multiforme: potential as a radiosensitizer. Ann Oncol. 2009;20:182-187.
20. Drappatz J, Brenner A, Wong ET, et al. Phase I study of GRN1005 in recurrent malignant glioma. Clin Cancer Res. 2013;19:1567-1576.
21. Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48:2192-2202.
22. Stommel JM, Kimmelman AC, Ying H, et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science. 2007;318:287-290.
23. Bogdahn U, Hau P, Stockhammer G, et al. Targeted therapy for high-grade glioma with the TGF-β2 inhibitor trabedersen: results of a randomized and controlled phase IIb study. Neuro Oncol. 2011;13:132-142.
24. Rodon Ahnert J, Baselga J, Calvo E, et al. First human dose (FHD) study of the oral transforming growth factor-β receptor I kinase inhibitor LY2157299 in patients with treatment-refractory malignant glioma [abstract]. J Clin Oncol. 2011;29(suppl):3011.